Profile data is unavailable for this security.
About the company
Racura Oncology Ltd, formerly Race Oncology Limited, is an Australia-based Phase III clinical biopharmaceutical company with a focus on cancer care. The Company's lead asset, RCDS1 (E,E-bisantrene), is a small molecule anticancer agent that primarily functions via G4-DNA and RNA binding, leading to potent inhibition of the important cancer growth regulator MYC. RCDS1 has demonstrated therapeutic activity in cancer patients with a well characterized safety profile. The Company is advancing a formulation of RCDS1 (RC220) to address the high unmet needs of patients across multiple oncology indications, with Phase III clinical programs in acute myeloid leukemia (AML), a Phase I a/b program in mutant epidermal growth factor receptor non-small cell lung cancer (EGFRm NSCLC), and a Phase I a/b program in combination with the anthracycline doxorubicin, where the Company is focused on delivering both cardioprotection and enhanced anticancer activity for solid tumor patients.
- Revenue in AUD (TTM)788.42k
- Net income in AUD-4.79m
- Incorporated2011
- Employees--
- LocationRacura Oncology LtdLevel 36, Gateway 1, Macquarie PlaceSYDNEY 2000AustraliaAUS
- Phone+61 28051-3043
- Websitehttps://www.raceoncology.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Arovella Therapeutics Ltd | 560.09k | -7.93m | 98.99m | 14.00 | -- | 5.21 | -- | 176.74 | -0.0069 | -0.0069 | 0.0005 | 0.0158 | 0.034 | -- | -- | -- | -48.19 | -75.94 | -51.95 | -90.89 | -- | -- | -1,415.18 | -2,386.13 | -- | -- | 0.00 | -- | 237.44 | -1.82 | 14.14 | -- | 1.23 | -- |
| Tetratherix Ltd | 1.14m | -9.43m | 105.17m | -- | -- | 7.15 | -- | 92.04 | -0.1873 | -0.1873 | 0.0227 | 0.5414 | 0.0688 | -- | 2.22 | -- | -56.71 | -- | -76.72 | -- | -172.06 | -- | -824.89 | -- | -- | -98.75 | 0.0697 | -- | 32.30 | -- | -269.05 | -- | -- | -- |
| Island Pharmaceuticals Ltd | 58.80k | -3.92m | 109.06m | -- | -- | 12.21 | -- | 1,854.82 | -0.0224 | -0.0224 | 0.0003 | 0.0303 | 0.0117 | -- | 0.1099 | -- | -77.95 | -72.12 | -90.37 | -81.53 | -- | -- | -6,666.91 | -19,239.15 | -- | -162.89 | 0.00 | -- | 1,148.41 | -- | -36.86 | -- | -- | -- |
| Paradigm Biopharmaceuticals Ltd | 7.11m | -18.77m | 114.21m | -- | -- | 4.78 | -- | 16.07 | -0.047 | -0.047 | 0.0183 | 0.0544 | 0.2684 | -- | 1.14 | -- | -70.91 | -67.55 | -80.99 | -75.98 | 99.71 | 99.24 | -264.18 | -527.01 | -- | -9,722.29 | 0.0003 | -- | 10.29 | 8.87 | 68.04 | -- | -- | -- |
| Bioxyne Ltd | 28.43m | 4.90m | 134.39m | 16.00 | 25.86 | 10.47 | 23.63 | 4.73 | 0.0023 | 0.0023 | 0.0132 | 0.0057 | 2.16 | 6.30 | 17.06 | -- | 37.31 | -28.17 | 55.76 | -38.16 | 36.32 | 35.97 | 17.24 | -24.14 | 1.90 | -- | 0.1125 | -- | 204.87 | 65.94 | 138.29 | -- | 127.89 | -- |
| Actinogen Medical Ltd | 685.26k | -14.73m | 141.94m | -- | -- | 7.10 | -- | 207.13 | -0.005 | -0.005 | 0.0002 | 0.0058 | 0.0299 | -- | 0.0907 | -- | -64.34 | -53.87 | -76.58 | -59.25 | -- | -- | -2,149.88 | -3,680.96 | -- | -231.81 | 0.1511 | -- | 135.46 | 48.76 | -12.94 | -- | 10.81 | -- |
| Nyrada Inc | 2.52m | -5.58m | 162.89m | -- | -- | 16.43 | -- | 64.63 | -0.025 | -0.025 | 0.0114 | 0.0405 | 0.2978 | -- | -- | -- | -65.88 | -48.87 | -70.89 | -53.88 | -- | -- | -221.21 | -195.83 | -- | -171.72 | 0.00 | -- | -24.81 | 18.93 | -248.28 | -- | -- | -- |
| Dimerix Ltd | 5.91m | -13.25m | 285.19m | 0.00 | -- | 21.25 | -- | 48.22 | -0.0239 | -0.0239 | 0.0106 | 0.0224 | 0.096 | -- | 22.53 | -- | -21.50 | -48.20 | -27.12 | -68.49 | -- | -- | -224.08 | -932.89 | -- | -- | 0.0072 | -- | 913.54 | 365.69 | 22.39 | -- | -- | -- |
| Cogstate Ltd | 78.92m | 15.17m | 392.86m | 61.00 | 26.44 | 5.41 | 20.08 | 4.98 | 0.0866 | 0.0866 | 0.4498 | 0.4233 | 0.8722 | -- | 4.88 | -- | 16.76 | 11.82 | 20.90 | 16.38 | 56.47 | 56.32 | 19.22 | 14.87 | -- | -- | 0.008 | 6.89 | 22.25 | 18.44 | 86.15 | -- | -0.4007 | -- |
| Racura Oncology Ltd | 788.42k | -4.79m | 448.72m | -- | -- | 26.80 | -- | 569.13 | -0.0282 | -0.0282 | 0.0043 | 0.0922 | 0.0418 | -- | 11.64 | -- | -25.38 | -41.75 | -27.84 | -44.07 | -- | -- | -607.20 | -2,015.76 | -- | -- | 0.00 | -- | -5.30 | 142.92 | 65.36 | -- | -- | -- |
| Immutep Ltd | 4.13m | -83.92m | 567.38m | 19.00 | -- | 5.74 | -- | 137.30 | -0.0573 | -0.0573 | 0.0028 | 0.0671 | 0.0251 | -- | 0.26 | -- | -50.93 | -32.47 | -61.41 | -34.65 | -- | -- | -2,030.67 | -21,963.05 | -- | -- | 0.0121 | -- | -49.76 | -62.18 | -43.82 | -- | 69.56 | -- |
| Opthea Ltd | 35.19k | -229.15m | 820.79m | 5.00 | -- | -- | -- | 23,323.44 | -0.1876 | -0.1876 | 0.00003 | -0.2299 | 0.0002 | -- | 0.1324 | -- | -132.57 | -123.14 | -- | -214.28 | -- | -- | -651,164.00 | -159,023.40 | -- | -11.15 | -- | -- | -79.95 | -15.80 | 26.09 | -- | 38.73 | -- |
